This biotech company has a track record of commercializing products and delivering growth. It also has strengths in research and development.

China Universal Asset Management Co. Ltd. cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 13.0% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 21,359 shares of the biopharmaceutical company's stock after selling 3,178 shares during the quarter.

FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability

CenterBook Partners LP grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 10.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 57,223 shares of the biopharmaceutical company's stock after acquiring an additional 5,632 shares during the

Ocular Therapeutix said on Tuesday its experimental eye disease drug was more effective in helping patients maintain their vision compared to Regeneron's approved treatment Eylea in a late-stage trial.

CENTRAL TRUST Co cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 56.5% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 519 shares of the biopharmaceutical company's stock after selling 673 shares during the period. CENTRAL TRUST

Assetmark Inc. lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 83.7% in the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 20,819 shares of the biopharmaceutical company's stock after selling 106,802 shares during the quarter. Assetmark Inc.'s holdings in Regeneron Pharmaceuticals were

Advisors Asset Management Inc. reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 23.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,426 shares of the biopharmaceutical company's stock after selling 1,062 shares during the quarter. Advisors

Caprock Group LLC purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) in the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 2,528 shares of the biopharmaceutical company's stock, valued at approximately $1,471,000. Other institutional investors also recently bought and sold shares of

Insight into Mason Hawkins (Trades, Portfolio)' Fourth Quarter 2025 Investment Strategy Mason Hawkins (Trades, Portfolio) recently submitted the 13F filing for